RetinDR, by Retinset

The first topical ophthalmic formulation (eye drops) that effectively prevents and/or treats the retinal neurodegeneration induced by diabetes (diabetic retinopathy) and/or aging

Diabetic retinopathy (DR) is the leading cause of blindness among working-aged adults. About 93 million people worldwide and 3%-4.1% of Europeans suffer from this disease. The early stages of DR usually have no symptoms; however, when the disease progresses it affects vision: blurred vision, seeing double, difficulty reading, spots or floaters in the field of vision and loss of peripheral vision. Current treatments are quite aggressive, only indicated in advanced stages of the disease, have significant side effects and their effectiveness is limited.

Our client, the spanish company Retinset, has developed RetinDR, a topical ophthalmic formulation (eye drops) that effectively prevents and/or treats the retinal neurodegeneration induced by diabetes (diabetic retinopathy) and/or aging.

In order to carry out the feasibility study for this project and develop a business plan to bring it to market, Retinset submitted their proposal to the May call for Phase 1 of the SME Instrument and we are very pleased to announce that they have obtained the necessary grant to carry out this initial phase of their project.

We at Aristos want to congratulate Retinset for this success and we are very happy to have been collaborating with them in this beautiful project that will help hundreds of people improve their quality of life.